Stockscreener 앱 받기
625.65
2.37%
-15.21
시간 외 거래:
625.80
0.15
+0.02%
Lilly Eli Co 주식(LLY)의 최신 뉴스
Lilly launches "The Court Is Hers™" to help more girls get in the game - Eli Lilly and Company
Eli Lilly (LLY) Partners With Senderra For Innovative Digital Patient Care Solution - uk.finance.yahoo.com
Eli Lilly’s Stock Dips Amid Weight-Loss Pill Setback - TipRanks
Earnings Beat: Eli Lilly and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $825 to $1,190 - 富途牛牛
Benzinga Bulls And Bears: AMD, Apple, Eli Lilly — And Wall Street Treads Water - Benzinga
IonQ, Eli Lilly, Monster, Crocs, Kratos Trending by Analysts - TipRanks
BMO Raises Eli Lilly (LLY) Price Target, Keeps Outperform Rating - Insider Monkey
Director’s Bold Move: Major Investment in Eli Lilly & Co Stock - TipRanks
Why Novo Nordisk Stock Flew Higher on Friday - The Motley Fool
Lilly Shares Slide Following Weight Loss Pill Trial Results - InkFreeNews.com
Celltrion in talks to buy Eli Lilly plant in US for $504 million - KED Global
Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst - Benzinga
Is Eli Lilly's 14% Post-Earnings Slide a Buy-the-Dip Opportunity? - MSN
ETFs In Focus On Eli Lilly's Solid Q2 Earnings, Weak Obesity Data - Barchart.com
Eli Lilly Stock Collapsed On Its Shocking Obesity Flop — Is It Now A Sell? - Investor's Business Daily
Eli Lilly stock rating reiterated at Overweight by JPMorgan - Investing.com South Africa
Eli Lilly Stock (LLY) Continues to Sink as Enthusiasm for Obesity Pill Fades - TipRanks
Eli Lilly: 50% Upside For LLY Stock? - Forbes
Eli Lilly stock price target lowered to $895 by UBS on orfo data concerns - Investing.com
Eli Lilly defends itself after disappointing obesity data: “It’s tough to compare" - medwatch.com
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried? - The Motley Fool
Eli Lilly and Company (NYSE:LLY) Q2 2025 Earnings Call Transcript - Insider Monkey
Novo Nordisk execs respond to rival's tablet data: "We can make a really great launch in the US” - medwatch.com
Eli Lilly’s once daily oral pill shows major weight loss in trials: Is this easier to use than taking a shot? - The Indian Express
Morgan Stanley reiterates Overweight rating on Eli Lilly stock, citing GLP-1 growth - Investing.com
Eli Lilly price target lowered to $895 from $1,050 at UBS - TipRanks
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY) - StreetInsider
Morgan Stanley trims Eli Lilly price target, calls selloff ‘overdone’ - TipRanks
Eli Lilly & Co: Strong Buy Rating Backed by Robust Performance and Growth Prospects - TipRanks
Eli Lilly Earnings: Weak Orforglipron Obesity Data Weighs Down a Strong Quarter - Morningstar
Eli Lilly sees challenges in the US: Compounders are rampant while CVS prefers Novo Nordisk - medwatch.com
Eli Lilly and Company (NYSE: LLY) | Stock Quote, Chart, Outlook - AskTraders.com
Eli Lilly and Co (LLY) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Eli Lilly and Co (LLY) Q2 2025 Earnings Call Highlights: Record - GuruFocus
Eli Lilly, a U.S. pharmaceutical company that has led the world's largest anti-obesity drug market - 매일경제
Eli Lilly's orforglipron achieves weight loss goal but stock drops 14%CHOSUNBIZ - Chosunbiz
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound - Stocktwits
Eli Lilly (LLY) Stock: Drops 14% Despite 38% Revenue Growth Led by Zepbound and Mounjaro - CoinCentral
Chugai Highlights Eli Lilly’s Positive Phase 3 Results for Orforglipron - TipRanks
Eli Lilly's Share Price Sheds Some Weight: This Doesn't Mean To Pile In (NYSE:LLY) - Seeking Alpha
Eli Lilly could get $100M in tax credits for Wisconsin expansion - Finance & Commerce
Pill-version of popular weight loss drugs could be available, Eli Lilly officials say - WUSA9
Lilly's beat-and-raise quarter can't escape orforglipron's shadow - FirstWord Pharma
Earnings live: Eli Lilly stock slides, Pinterest sells off, Block gains after hours - ca.finance.yahoo.com
Earnings live: Eli Lilly stock slides, Pinterest sells off, Expedia and Block gain after hours - uk.finance.yahoo.com
Lilly Falls as Weight-Loss Pill Data Overshadows Sales Beat - Bloomberg.com
Closing a zombie biotech, and Lilly’s disappointing obesity readout - statnews.com
Eli Lilly stock sell-off ‘overdone’ as weight-loss pill remains ‘commercially viable’ - Invezz
Eli Lilly weight loss pill shows promise, but not as strong as injectables - AOL.com
Why Eli Lilly (LLY) Shares Are Getting Obliterated Today - Yahoo Finance
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today? - Fast Company
Apple Jumps, Eli Lilly Crashes On Worst Day In 25 Years: What's Moving Markets Thursday? - MSN
Eli Lilly, Fortinet Lead Thursday Market Cap Stock Movers - Investing.com
Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease - Seeking Alpha
Why Eli Lilly Stock Is Plunging Today - AOL.com
Market movers: Duolingo, Eli Lilly, Warner Bros, Crocs... - Proactive financial news
Eli Lilly, Fortinet Lead Thursday Market Cap Stock Movers By Investing.com - Investing.com Nigeria
Lilly: Q2 Earnings Snapshot - The Washington Post
Eli Lilly CEO criticizes Trump's demands for lower drug prices in the US - medwatch.com
Eli Lilly Co. Q2 FY2025 Earnings TranscriptEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly Crashes On Worst Day In 25 Years: Markets TodayApple (NASDAQ:AAPL) - Benzinga
Lilly shares tumble amid questions regarding weight-loss pill - Inside INdiana Business
Earnings call transcript: Eli Lilly Q2 2025 beats forecasts, stock drops By Investing.com - Investing.com South Africa
Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly - Yahoo Finance
1.05%
0.41%
자본화:
|
볼륨(24시간):